SCHEMBL2913113

SCHEMBL2913113

Cc1cc(OCCCC(=O)O)c(OCCCC(=O)O)cc1-c1cccc(C=O)c1C

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.48
FABP3 P05413 6/20 0.44
PTGDR2 Q9Y5Y4 2/20 0.44
FABP4 P15090 4/20 0.41
FFAR4 Q5NUL3 3/20 0.40
S1PR5 Q9H228 2/20 0.40
PPARG P37231 1/20 0.40
PPARD Q03181 1/20 0.40
PPARA Q07869 1/20 0.40
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
SNCA P37840 1/20 0.38
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
FFAR1 O14842 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2909825 0.85 ALDH1A1 (0.41) PTGDR2PDCD1CD274ALDH1A1HPGD
SCHEMBL2913115 0.83 ALDH1A1 (0.40) PTGDR2PDCD1CD274ALDH1A1HPGD
SCHEMBL13140089 0.79 RARB (0.40) PTGDR2PDCD1CD274ALDH1A1HPGD
SCHEMBL4266947 0.77 PTGDR2 (0.50) TSHRPTGDR2S1PR5PPARGPPARD
SCHEMBL13117586 0.76 FFAR1 (0.38) TSHRPTGDR2PDCD1CD274ALDH1A1
SCHEMBL13117607 0.75 SMN1; SMN2 (0.37) PTGDR2PPARDPDCD1CD274ALDH1A1
SCHEMBL5304037 0.74 PTGDR2 (0.70) TSHRFABP3PTGDR2FABP4FFAR4
SCHEMBL13139833 0.72 ERN1 (0.45) TSHRPDCD1CD274ALDH1A1HPGD
SCHEMBL10374308 0.72 PTGDR2 (0.54) TSHRPTGDR2FFAR4PPARAALDH1A1
SCHEMBL7082490 0.72 FFAR4 (0.50) TSHRFABP3PTGDR2FFAR4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND GPR119, GLP1R, GPR4 TSHR 877/4885FABP3 3112/4885PTGDR2 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.